CONNECTA Therapeutics

#CONNECTA Therapeutics #Funding #Phase II trial #Rare disease

€3.1 million to support Fragile X syndrome programme

CONNECTA Therapeutics has closed a €3.1 million financing led by new investor Clave Capital through its Innvierte Science Tech Clave Innohealth, FCR fund.  The funds will support CONNECTA in accelerating the Phase IIa clinical trial of CTH120 in adult males with Fragile X syndrome (FXS).  Jordi Fàbrega, Co‑Founder and CEO… Read More

#Business & Investment #News